YOLFTbeta
Raphas Co. Ltd

Raphas Co. Ltd

214260 · KQ · Healthcare / Biotechnology

7,630.00KRW+180.00 (+2.42%)

Price History

Full chart

Market Stats

Previous Close7,450.00
Open7,700.00
Day Range7,300.00 – 7,770.00
52-Week Range6,240.00 – 16,670.00
Volume8.42K
Market Cap64.41B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.58
50-Day Avg8,228.40
200-Day Avg9,707.45

About

Raphas Co., Ltd. manufactures and sells biodegradable microneedles in Korea. The company offers skin care, medical device, whitening care, and wrinkle care under the Acropass brand; and health food product under the FitKong brand. It also supplies double-layer microneedle manufacturing technology; and provides original development manufacturing, and contract development and manufacturing organization services. The company was incorporated in 2006 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Dohyeon Jeong
  • Employees79
  • Headquarters62, Magokjungang 8-ro 1-gil, Seoul, South Korea, 07793, Korea
  • Websitehttps://www.raphas.co.kr

Leadership

  • Mr. Dohyeon JeongChief Executive Officer · b. 1969

Financials

Income Statement

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue6.94B10.05B18.17B17.86B20.34B23.64B27.94B27.22B30.99B
Growth (%)-+44.89%+80.75%-1.69%+13.87%+16.22%+18.18%-2.58%+13.86%
Cost of Revenue4.65B6.40B9.92B11.56B10.81B12.60B15.32B15.12B16.93B
Gross Profit2.29B3.65B8.25B6.30B9.52B11.04B12.62B12.09B14.06B
Gross Margin33.01%36.31%45.41%35.26%46.83%46.69%45.16%44.43%45.37%
Operating Expense6.86B7.95B8.68B10.57B11.57B17.47B19.75B17.57B17.09B
Operating Income-4.57B-4.30B-433.08M-4.28B-2.05B-6.43B-7.14B-5.48B-3.03B
Operating Margin-65.87%-42.76%-2.38%-23.94%-10.07%-27.20%-25.55%-20.13%-9.79%
EBITDA------2.83B148.13M3.17B2.93B
EBITDA Margin------11.97%0.53%11.64%9.46%
Net Income-5.40B-3.84B125.23M-4.54B4.93B-8.51B-8.80B-4.77B-4.31B
Net Income Margin-77.90%-38.23%0.69%-25.42%24.24%-36.00%-31.52%-17.53%-13.92%
R&D---3.56B3.54B4.30B3.99B2.86B2.67B
R&D as % of Total Revenue---19.92%17.39%18.21%14.27%10.51%8.62%
Interest Expense000224.78M1.06B2.89B5.36B4.84B4.25B
Interest Expense % of Total Revenue0.00%0.00%0.00%1.26%5.20%12.22%19.19%17.79%13.72%

Balance Sheet

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets34.81B34.51B62.88B59.83B97.84B96.06B100.40B76.09B75.08B
Total Liabilities11.07B14.38B15.05B15.65B45.49B55.13B68.10B46.73B44.36B
Total Equity23.74B20.13B47.83B44.18B52.36B40.93B29.54B29.36B28.33B
Cash2.36B5.58B3.00M3.00M7.52B7.73B18.13B13.30B15.34B
Total Debt7.55B8.81B10.58B9.56B-----
Net Debt---4.21B13.24B21.11B27.66B15.31B18.12B

Cash Flow

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.55B-651.09M-2.77B903.85M862.01M-3.63B-1.81B4.88B1.43B
Investing Cash Flow-2.48B1.30B-27.08B1.85B-31.29B3.65B4.30B14.13B-
Financing Cash Flow2.97B2.54B29.36B-1.39B31.65B569.24M9.17B-23.27B-
Capital Expenditure9.50B2.06B8.12B2.17B1.89B7.64B4.26B1.69B765.20M
Free Cash Flow---8.53B-1.76B-1.03B-11.28B-6.07B3.19B667.43M
FCF to OCF--307.75%-195.17%-119.17%310.31%335.63%65.30%46.59%

Earnings

Report DateMar 19, 2020May 14, 2020Aug 14, 2020Nov 13, 2020Feb 25, 2021May 14, 2021Aug 13, 2021Nov 11, 2021Feb 24, 2022May 13, 2022Aug 12, 2022Nov 11, 2022Feb 22, 2023Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------------
EPS Actual-197.4199.00-306.00-126.00-207.5080.00-26.0028.00475.51-133.00-339.63-170.15-344.78-48.16-298.23-297.69-391.83-163.67334.84-1091.31393.00-129.75-58.24-140.00-185.11-99.34-227.20
Surprise---------------------------
TimingAfter-hoursPre-market-Pre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market--------------

Key Statistics & Ratios

Market Cap64.41B
Enterprise Value74.28B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.14
Price / Book2.51
Revenue (TTM)30.16B
Gross Profit (TTM)13.08B
EBITDA-29.42M
Profit Margin-18.17%
Operating Margin-23.35%
Return on Equity-18.71%
Return on Assets-3.22%
Shares Outstanding8.41M
Shares Float6.60M
Beta0.58
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%